Global Ischemic Stroke Market and Forecast Analysis 2019-2024: Market Growth will Slow as Plavix Continues to Lose Market Share as Generic Clopidogrel Uptake Increases - ResearchAndMarkets.com

DUBLIN--()--The "Ischemic Stroke Market and Forecast Analysis 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.

Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death. The majority of strokes occur due to blockages, and these are known as ischemic strokes. Strokes caused by bleeding are known as hemorrhagic strokes.

Market Snapshot

  • Market growth will slow as Plavix continues to lose market share as generic clopidogrel uptake increases.
  • Alteplase is prescribed to 65% of ischemic stroke patients in the US, Japan, and five major EU markets who receive thrombolytic therapy as an acute treatment.
  • Overall disease burden is expected to greatly increase, with ischemic stroke more common than hemorrhagic stroke.
  • Activase will continue to experience strong uptake while Aggrenox and Plavix face declining sales.
  • The large-scale Xarelto study was recently suspended, and there are no other pipeline drugs in Phase III trials.

Key Topics Covered:

FORECAST: ISCHEMIC STROKE

Overview

Market Overview And Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile: Aspirin

Product Profile: Plavix

TREATMENT: ISCHEMIC STROKE

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Current Treatment Options

Prescribing Trends

EPIDEMIOLOGY: STROKE

Overview

Disease Background

Methodology

Forecast

Bibliography

Appendix: Additional Sources

MARKETED DRUGS: ISCHEMIC STROKE

Overview

Executive Summary

Product Overview

Product Profile: Activase

Product Profile: Aggrenox

Product Profile: Aspirin

Product Profile: Plavix

PIPELINE: ISCHEMIC STROKE

Overview

Executive Summary

Clinical Pipeline Overview

Recently Discontinued Drugs

Additional Pharma Intelligence Pipeline Resources

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/53jhbx

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology